Lifecore Biomedical
Develops and manufactures sterile injectable products and pharmaceutical-grade hyaluronic acid.
Something off on this page? Send us feedback.
Profile
Provides development, formulation, cGMP manufacturing, and aseptic fill-finish for sterile injectable pharmaceutical and medical-device products. Its fermentation-based hyaluronic-acid capability supplies pharmaceutical-grade HA as bulk material and in formulated, filled injectable products.
Develops, formulates, and manufactures sterile injectable pharmaceutical and medical-device products, including filled syringes, vials, and cartridges. Its integrated CDMO services cover development, cGMP manufacturing, formulation, and aseptic fill-finish, alongside pharmaceutical-grade hyaluronic acid supplied as bulk material and used in formulated products.
Operations are concentrated in Chaska, Minnesota, and its full-time workforce was entirely based in the United States as of the context filing. The business depends on fermentation-based HA capability and on executing sterile manufacturing and aseptic filling for complex products. It has operated as a standalone integrated CDMO since divesting its former food businesses.
Company facts
Key statistics
Year to date −41.4% · Average volume (30d) 128.3K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Jun 16, 2026 | Barrington | Target | $6 | $6.50 | ||
| Apr 29, 2026 | Barrington | Target | $6 | |||
| Mar 17, 2026 | Barrington Research | Upgrade | Market Perform | Outperform |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026Q2 FY26 | −$0.19 | −$0.19 | 0.0% | $34.2M | $23.2M | −32.1% | +2.07% |
| May 6, 2026Q3 FY26 | −$0.29 | −$0.43 | −48.3% | $26.0M | $23.2M | −10.6% | −3.83% |
| Mar 16, 2026 | −$0.29 | −$0.16 | +44.8% | $33.1M | $35.2M | +6.1% | −0.23% |
| Nov 6, 2025Q1 FY26 | −$0.30 | −$0.29 | +3.3% | $26.5M | $31.1M | +17.5% | +3.47% |
Financial highlights
| 12 quarters | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q3 FY26 | Q2 FY26 | Q4 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $35.2M | $36.4M | $31.1M | $23.2M | $34.2M | $34.2M | |
| Gross profit | $9.8M | $14.0M | $7.8M | $4.5M | $12.1M | $12.1M | |
| Operating income | −$9.0M | $5.3M | −$3.1M | −$4.7M | $2.6M | $2.6M | |
| Net income | −$14.8M | −$1.1M | −$10.0M | −$15.0M | −$6.2M | −$6.2M | |
| Diluted EPS | −$0.47 | −$0.06 | −$0.29 | −$0.43 | −$0.19 | −$0.19 | |
| Gross margin | 28.0% | 38.4% | 25.0% | 19.2% | 35.3% | 35.3% | |
| Operating margin | -25.7% | 14.6% | -9.9% | -20.1% | 7.5% | 7.5% |
Fiscal years (4-quarter sums)FY22 $170.1M · FY23 $97.6M · FY24 $128.3M · FY25 $128.9M · FY26 $122.6M
Balance sheet, Jun 30, 2026Cash & short-term investments $17.2M · Total debt $155.1M · Total assets $229.5M · Shareholders' equity $16.1M
Dividends
No dividends on record.
Ownership
Shares outstanding 37.51M · Float 33.87M · 90.3% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Legion Partners Holdings, LLC | 6.79M | 17.10% | 13D | Jul 2, 2026 |
| Wynnefield Capital Inc | 4.70M | 12.54% | 13F | Aug 14, 2026 |
| Greenhaven Road Investment Management, L.P. | 3.19M | 8.51% | 13F | Aug 14, 2026 |
| 325 Capital LLC | 2.90M | 7.72% | 13F | Aug 14, 2026 |
| 22NW GP, Inc. | 2.71M | 6.74% | 13D | Jul 2, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
- Thermo Fisher Scientific
End-to-end CDMO with sterile injectable fill-finish capabilities
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Lifecore Biomedical | $4.54 | +0.11% | $170.3M | — | — | 1.4 | −36.4% |
| Thermo Fisher Scientific | $620.01 | −0.32% | $231.22B | 33.5 | 23.7 | 5.0 | +10.5% |
| Median | 33.5 | 23.7 | 5.0 | +10.5% |